The decrease of MAF1 RNA and protein expression in breast cancer (Fig 2), including HER2-positive breast cancer (Fig 2C), prompted us to investigate whether anti-HER2 therapies regulate MAF1 expression. Here, ERBB2 is linked to breast carcinoma.